Phillips-Medisize, GlucoModicum Team Up on Needle-Free CGM

Phillips-Medisize, a Molex company, has partnered with GlucoModicum to develop a needle-free continuous glucose monitor (CGM).
 
GlucoModicum is a Finland-based medtech firm that Phillips-Medisize will join hands with to design and eventually commercialize a proprietary non-invasive, wearable device that purports to remove technology and patient care roadblocks to CGM.
 
“We wanted to create a solution that is needle free, accurate and more affordable so people would better monitor their glucose,” GlucoModicum managing director Jokke Mäki told the press. “Working with Phillips-Medisize, we applied compelling science to develop a world-class product that may help billions of people better manage their diabetes.”
 
GlucoModicum has discovered that magnetohydrodynamic (MHD) technology could be leveraged to apply a small amount of energy to interstitial fluid to drive it to the skin’s surface for quick, easy glucose sample extraction.
 
The new Talisman device is designed to adhere to the arm. It integrates with MHD tech, ultra-sensitive biosensors, and advanced algorithms and connects to a smartphone app to collect data and report. (The device isn’t yet FDA approved and doesn’t have a CE mark.)
 
“We started with ideas, concepts and drawings,” said Phillips-Medisize’s business development manager Homer Fairley. “The day we provided the finished sample product to GlucoModicum was a moment of celebration for both parties, as it really brought the possibilities to life. Now that there is a proven concept, we look forward to the opportunity to leverage Phillips-Medisize’s high-volume manufacturing capabilities to produce hundreds of millions of units on time and in a cost-effective manner. That’s a big benefit to this project.”
 
In November 2022, GlucoModicum published results of its proprietary MHD technology’s safety, efficacy, and effectiveness in Scientific Reports, based on glucose tolerance tests conducted on five healthy volunteers. The solution was found to be 13 times more effective than other needle-free approaches tested to extract interstitial fluid from the skin.